New Test to Predict Primary Melanoma Progression

New Test to Predict Primary Melanoma Progression

21 January 2020

Australian researchers have played a critical role in the discovery of a potential new test to predict which early stage melanoma patients are at high risk of their disease recurring and progressing.

A joint study led by researchers from Melanoma Institute Australia, The University of Sydney, Harvard Medical School, Sydney Local Health District and Adaptive Biotechnology analysed immune cells (known as T-cells) in primary melanoma samples taken from 209 patients, 164 of whom came from MIA.

The study, published today in Nature Cancer, found that patients with a T-cell fraction (TCFr) of less than 20% in their primary melanoma were two-and-a-half times more likely to have disease progression than those with more than 20% TCFr.

The study was jointly led by Dr James Wilmott and Co-Medical Director Professor Richard Scolyer from Melanoma Institute Australia and researchers from Harvard Medical School.

‘These findings suggest analysing TCFr in primary melanomas is a valuable tool for predicting which patients are at risk of developing metastatic melanoma, ’ Dr Wilmott said.

‘This could enable us to personalise treatment for each patient based on their individual risk of recurrence and progression, and potentially target them earlier with immunotherapy,’ Professor Scolyer added.

Australia has one of the highest melanoma rates in the world, with one person diagnosed every 30 minutes and one person dying every five hours from disease.

While 90% of early stage melanomas are cured with surgery alone, a subset of patients will recur metastatically within five years.

Recent advances in targeted and immunotherapies have significantly improved outcomes for Stage IV melanoma patients. However, the management of primary melanoma has remained relatively unchanged, with prognosis based principally on histopathological factors such as tumour thickness and ulceration.

‘This test offers the ability to identify primary melanoma patients at high risk of developing metastatic disease at their initial diagnosis,’ Dr Wilmott said. ‘These patients may benefit from close monitoring or the addition of adjuvant treatments to prevent their disease progressing.’ 

MIA Co-Medical Director opens SMR Congress in USA
21 Nov 2019

MIA Co-Medical Director opens SMR Congress in USA

Professor Georgina Long has today opened the Society for Melanoma Research 2019 Congress in Salt Lake City, Utah.

Highly Cited Researchers List names MIA Co-Medical Directors
20 Nov 2019

Highly Cited Researchers List names MIA Co-Medical Directors

MIA’s Co-Medical Directors, Professor Georgina Long and Professor Richard Scolyer, have both been named Highly Cited Researchers, according to the Clarivate Analytics Highly Cited Researchers 2019 list.

MPA and MIA collaboration
07 Nov 2019

MPA and MIA collaboration

Melanoma Patients Australia (MPA) and Melanoma Institute Australia (MIA) have announced a new multi-year agreement to provide enhanced support services for melanoma patients nationally.

Community Fundraising October Wrap-Up
04 Nov 2019

Community Fundraising October Wrap-Up

It is time again to say thank you to our incredible community fundraisers who are helping us get closer to our goal of zero deaths from melanoma.

Promising data for advanced melanoma patients
09 Oct 2019

Promising data for advanced melanoma patients

MIA has presented promising data regarding progression-free survival rates for advanced melanoma patients at the ESMO 2019 Congress in Barcelona.

Melanoma Information Forum
04 Oct 2019

Melanoma Information Forum

We are delighted to partner with Melanoma Patients Australia to host a Melanoma Information Forum at The Poche Centre on 6th November.

Community Fundraising September Wrap-Up
02 Oct 2019

Community Fundraising September Wrap-Up

Another month has flown by and yet again we have a host of amazing community fundraisers who generously gave up their time to help us reach our goal of zero deaths from melanoma.

Notice for Supporters to Submit to PBAC
26 Sep 2019

Notice for Supporters to Submit to PBAC

Comments in favour of giving patients with BRAF-positive melanoma access to first-line immunotherapy need to be submitted online prior to October 9, 2019.

Tune into Jay's Longest Melanoma March Channel 10 documentary
16 Sep 2019

Tune into Jay's Longest Melanoma March Channel 10 documentary

Jay's Longest Melanoma March documentary is screening this Sunday 22 September at 1pm (AEST) on Channel 10, capturing behind the scenes of the 2000km walk, Adelaide to Sydney in 50 days. Uniting to end melanoma.

Professor Georgina Long Co-Medical Director named Women of Influence in Australian Financial Review Top 100 List
11 Sep 2019

Professor Georgina Long Co -Medical Director named Women of Influence in AFR Top 100 List

We are proud to announce that our Professor Georgina Long Co -Medical Director Melanoma Institute Australia has been named in the Top 100 Financial Review 2019 Women of Influence.

Community Fundraising August Wrap-Up
04 Sep 2019

Community Fundraising August Wrap-Up

It’s been a month since we highlighted some of our incredibly generous community fundraisers. We thought we’d have a look back at August and put the spotlight on more of the wonderful people who give up their time to fundraise for MIA, so we can continue to edge closer to our goal of zero deaths from melanoma.

From Lab Coats To Lycra - Australian Melanoma experts take on world Triathlon championships
02 Sep 2019

From Lab Coats To Lycra - Australian Melanoma experts take on world Triathlon championships

They are a formidable team - in work and in play  –  and one set to make history on both fronts.

Melanoma Institute Australia hosts first SunSafe Student Ambassador Program for 2019
30 Aug 2019

Melanoma Institute Australia hosts SunSafe Student Ambassador Programs 2019

This week, Melanoma Institute Australia hosted the first of six SunSafe Student Ambassador Programs for 2019.

Tags: SunSafe
Australia at risk of falling behind USA and Europe in preventing deadly recurrence of Melanoma
23 Aug 2019

Australia at risk of falling behind USA and Europe in preventing deadly recurrence of Melanoma

Federal government urged to provide certainty of access to immunotherapy for high risk melanoma patients.

Team Melanoma smashes City2Surf
16 Aug 2019

Team Melanoma smashes City2Surf

We want to thank every member of Team Melanoma and everyone who donated to them. With your help, we are moving closer to our goal of zero deaths from melanoma!

Ready to run over melanoma at City2Surf 2019
08 Aug 2019

Ready to run over melanoma at City2Surf 2019

Lauren O'Brien tells us why she's running for a cause close to her heart

Community Fundraising July Wrap-Up
01 Aug 2019

Community Fundraising July Wrap-Up

MIA could not do what we do without the incredible support and effort of our community fundraisers. We’d like to highlight some of the wonderful events organised by our community in the month of July that are helping us move closer to our goal of zero deaths from melanoma.

Breast cancer drug may hold key to tackling most deadly type of melanoma
23 Jul 2019

Breast cancer drug may hold key to tackling most deadly type of melanoma

An international study, led by researchers from Melanoma Institute Australia, QIMR Berghofer Medical Research Institute and The University of Sydney as part of the Australian Melanoma Genome Project, has discovered that a drug traditionally used to treat a type of breast cancer may hold the key to treating an aggressive and deadly form of melanoma.

MIA takes centre stage at leading cancer conference
05 Jun 2019

MIA takes centre stage at leading cancer conference

Researchers from Melanoma Institute Australia took centre stage at the American Society of Clinical Oncology Annual Meeting in Chicago. Results presented by MIA’s contingent have the potential to create better patient outcomes and change the way advanced melanoma is treated .

International Clinical Trials Day 2019
20 May 2019

International Clinical Trials Day 2019

Today is International Clinical Trials Day – a day to recognise and thank the amazing people who conduct, organise, and coordinate clinical trials.